These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

264 related items for PubMed ID: 33648930

  • 1. Cancer-Specific Targeting of Taurine-Upregulated Gene 1 Enhances the Effects of Chemotherapy in Pancreatic Cancer.
    Tasaki Y, Suzuki M, Katsushima K, Shinjo K, Iijima K, Murofushi Y, Naiki-Ito A, Hayashi K, Qiu C, Takahashi A, Tanaka Y, Kawaguchi T, Sugawara M, Kataoka T, Naito M, Miyata K, Kataoka K, Noda T, Gao W, Kataoka H, Takahashi S, Kimura K, Kondo Y.
    Cancer Res; 2021 Apr 01; 81(7):1654-1666. PubMed ID: 33648930
    [Abstract] [Full Text] [Related]

  • 2. The role of DPYD and the effects of DPYD suppressor luteolin combined with 5-FU in pancreatic cancer.
    Kato H, Sato M, Naiki-Ito A, Inaguma S, Sano M, Komura M, Nagayasu Y, Xiaochen K, Kato A, Matsuo Y, Ijichi H, Takahashi S.
    Cancer Med; 2024 Aug 01; 13(16):e70124. PubMed ID: 39158384
    [Abstract] [Full Text] [Related]

  • 3. Tumor-Specific Delivery of 5-Fluorouracil-Incorporated Epidermal Growth Factor Receptor-Targeted Aptamers as an Efficient Treatment in Pancreatic Ductal Adenocarcinoma Models.
    Mahajan UM, Li Q, Alnatsha A, Maas J, Orth M, Maier SH, Peterhansl J, Regel I, Sendler M, Wagh PR, Mishra N, Xue Y, Allawadhi P, Beyer G, Kühn JP, Marshall T, Appel B, Lämmerhirt F, Belka C, Müller S, Weiss FU, Lauber K, Lerch MM, Mayerle J.
    Gastroenterology; 2021 Sep 01; 161(3):996-1010.e1. PubMed ID: 34097885
    [Abstract] [Full Text] [Related]

  • 4. Histone deacetylase inhibition is synthetically lethal with arginine deprivation in pancreatic cancers with low argininosuccinate synthetase 1 expression.
    Kim SS, Xu S, Cui J, Poddar S, Le TM, Hayrapetyan H, Li L, Wu N, Moore AM, Zhou L, Yu AC, Dann AM, Elliott IA, Abt ER, Kim W, Dawson DW, Radu CG, Donahue TR.
    Theranostics; 2020 Sep 01; 10(2):829-840. PubMed ID: 31903153
    [Abstract] [Full Text] [Related]

  • 5. Inverse Correlation of STAT3 and MEK Signaling Mediates Resistance to RAS Pathway Inhibition in Pancreatic Cancer.
    Nagathihalli NS, Castellanos JA, Lamichhane P, Messaggio F, Shi C, Dai X, Rai P, Chen X, VanSaun MN, Merchant NB.
    Cancer Res; 2018 Nov 01; 78(21):6235-6246. PubMed ID: 30154150
    [Abstract] [Full Text] [Related]

  • 6. A novel chemoradiation targeting stem and nonstem pancreatic cancer cells by repurposing disulfiram.
    Cong J, Wang Y, Zhang X, Zhang N, Liu L, Soukup K, Michelakos T, Hong T, DeLeo A, Cai L, Sabbatino F, Ferrone S, Lee H, Levina V, Fuchs B, Tanabe K, Lillemoe K, Ferrone C, Wang X.
    Cancer Lett; 2017 Nov 28; 409():9-19. PubMed ID: 28864067
    [Abstract] [Full Text] [Related]

  • 7. lncRNA THAP9-AS1 Promotes Pancreatic Ductal Adenocarcinoma Growth and Leads to a Poor Clinical Outcome via Sponging miR-484 and Interacting with YAP.
    Li N, Yang G, Luo L, Ling L, Wang X, Shi L, Lan J, Jia X, Zhang Q, Long Z, Liu J, Hu W, He Z, Liu H, Liu W, Zheng G.
    Clin Cancer Res; 2020 Apr 01; 26(7):1736-1748. PubMed ID: 31831555
    [Abstract] [Full Text] [Related]

  • 8. Activation of PP2A and Inhibition of mTOR Synergistically Reduce MYC Signaling and Decrease Tumor Growth in Pancreatic Ductal Adenocarcinoma.
    Allen-Petersen BL, Risom T, Feng Z, Wang Z, Jenny ZP, Thoma MC, Pelz KR, Morton JP, Sansom OJ, Lopez CD, Sheppard B, Christensen DJ, Ohlmeyer M, Narla G, Sears RC.
    Cancer Res; 2019 Jan 01; 79(1):209-219. PubMed ID: 30389701
    [Abstract] [Full Text] [Related]

  • 9. LncRNA LUCAT1 contributes to cell proliferation and migration in human pancreatic ductal adenocarcinoma via sponging miR-539.
    Nai Y, Pan C, Hu X, Ma Y.
    Cancer Med; 2020 Jan 01; 9(2):757-767. PubMed ID: 31789465
    [Abstract] [Full Text] [Related]

  • 10. MicroRNA-323-3p inhibits cell invasion and metastasis in pancreatic ductal adenocarcinoma via direct suppression of SMAD2 and SMAD3.
    Wang C, Liu P, Wu H, Cui P, Li Y, Liu Y, Liu Z, Gou S.
    Oncotarget; 2016 Mar 22; 7(12):14912-24. PubMed ID: 26908446
    [Abstract] [Full Text] [Related]

  • 11. LncRNA TUG1 promoted viability and associated with gemcitabine resistant in pancreatic ductal adenocarcinoma.
    Yang F, Li X, Zhang L, Cheng L, Li X.
    J Pharmacol Sci; 2018 Jun 22; 137(2):116-121. PubMed ID: 29960845
    [Abstract] [Full Text] [Related]

  • 12. Long noncoding RNA TUG1 promotes cisplatin resistance in ovarian cancer via upregulation of DNA polymerase eta.
    Sonobe R, Yang P, Suzuki MM, Shinjo K, Iijima K, Nishiyama N, Miyata K, Kataoka K, Kajiyama H, Kondo Y.
    Cancer Sci; 2024 Jun 22; 115(6):1910-1923. PubMed ID: 38558246
    [Abstract] [Full Text] [Related]

  • 13. Cotargeting of MEK and PDGFR/STAT3 Pathways to Treat Pancreatic Ductal Adenocarcinoma.
    Sahu N, Chan E, Chu F, Pham T, Koeppen H, Forrest W, Merchant M, Settleman J.
    Mol Cancer Ther; 2017 Sep 22; 16(9):1729-1738. PubMed ID: 28619758
    [Abstract] [Full Text] [Related]

  • 14. LncRNA H19/miR-194/PFTK1 axis modulates the cell proliferation and migration of pancreatic cancer.
    Sun Y, Zhu Q, Yang W, Shan Y, Yu Z, Zhang Q, Wu H.
    J Cell Biochem; 2019 Mar 22; 120(3):3874-3886. PubMed ID: 30474270
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Inhibition of TGF-β signalling in combination with nal-IRI plus 5-Fluorouracil/Leucovorin suppresses invasion and prolongs survival in pancreatic tumour mouse models.
    Hong E, Park S, Ooshima A, Hong CP, Park J, Heo JS, Lee S, An H, Kang JM, Park SH, Park JO, Kim SJ.
    Sci Rep; 2020 Feb 19; 10(1):2935. PubMed ID: 32076068
    [Abstract] [Full Text] [Related]

  • 17. Small Nucleolar Noncoding RNA SNORA23, Up-Regulated in Human Pancreatic Ductal Adenocarcinoma, Regulates Expression of Spectrin Repeat-Containing Nuclear Envelope 2 to Promote Growth and Metastasis of Xenograft Tumors in Mice.
    Cui L, Nakano K, Obchoei S, Setoguchi K, Matsumoto M, Yamamoto T, Obika S, Shimada K, Hiraoka N.
    Gastroenterology; 2017 Jul 19; 153(1):292-306.e2. PubMed ID: 28390868
    [Abstract] [Full Text] [Related]

  • 18. Cotargeting of epidermal growth factor receptor and PI3K overcomes PI3K-Akt oncogenic dependence in pancreatic ductal adenocarcinoma.
    Wong MH, Xue A, Julovi SM, Pavlakis N, Samra JS, Hugh TJ, Gill AJ, Peters L, Baxter RC, Smith RC.
    Clin Cancer Res; 2014 Aug 01; 20(15):4047-58. PubMed ID: 24895459
    [Abstract] [Full Text] [Related]

  • 19. TIMP1 Triggers Neutrophil Extracellular Trap Formation in Pancreatic Cancer.
    Schoeps B, Eckfeld C, Prokopchuk O, Böttcher J, Häußler D, Steiger K, Demir IE, Knolle P, Soehnlein O, Jenne DE, Hermann CD, Krüger A.
    Cancer Res; 2021 Jul 01; 81(13):3568-3579. PubMed ID: 33941611
    [Abstract] [Full Text] [Related]

  • 20. Aspartate β-hydroxylase promotes pancreatic ductal adenocarcinoma metastasis through activation of SRC signaling pathway.
    Ogawa K, Lin Q, Li L, Bai X, Chen X, Chen H, Kong R, Wang Y, Zhu H, He F, Xu Q, Liu L, Li M, Zhang S, Nagaoka K, Carlson R, Safran H, Charpentier K, Sun B, Wands J, Dong X.
    J Hematol Oncol; 2019 Dec 30; 12(1):144. PubMed ID: 31888763
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.